Literature DB >> 14639954

[Three cases of idiopathic thrombocytopenic purpura showing an increase in the platelet count following clarithromycin treatment].

Masashi Ohe1, Michihumi Kohno.   

Abstract

Macrolides have immuno-modulatory effects as well as anti-bacterial effects. We successfully treated three idiopathic thrombocytopenic purpura (ITP) patients with clarithromycin (CAM). Case 1: A 69-year-old male ITP patient was treated with CAM at a dose of 400 mg/day. His platelet count increased from 5.6 x 10(4)/microliter to 10.1 x 10(4)/microliter. Case 2: A 72-year-old male ITP patient was treated with CAM at the same dose. The platelet count increased from 1.3 x 10(4)/microliter to 12.3 x 10(4)/microliter. Case 3: A 68-year-old female ITP patient was treated with CAM at the same dose. The platelet count increased from 2.3 x 10(4)/microliter to 13 x 10(4)/microliter. These facts suggest that CAM is useful in the treatment of ITP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14639954

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  4 in total

1.  Significance of lymphocyte counts at diagnosis in the management of ITP: the relationship between lymphocyte counts and treatment success in H. pylori-infected patients.

Authors:  Akihisa Nagata; Naohiro Sekiguchi; Miwa Kurimoto; Satoshi Noto; Naoki Takezako
Journal:  Int J Hematol       Date:  2015-01-28       Impact factor: 2.490

2.  Successful treatment with erythromycin for idiopathic thrombocytopenic purpura.

Authors:  Masashi Ohe; Satoshi Hashino
Journal:  Korean J Hematol       Date:  2011-06-21

Review 3.  Macrolides in chronic inflammatory skin disorders.

Authors:  Abdullateef A Alzolibani; Khaled Zedan
Journal:  Mediators Inflamm       Date:  2012-05-17       Impact factor: 4.711

Review 4.  Anti-inflammatory and Immunomodulatory Effects of Antibiotics and Their Use in Dermatology.

Authors:  Swetalina Pradhan; Bhushan Madke; Poonam Kabra; Adarsh Lata Singh
Journal:  Indian J Dermatol       Date:  2016 Sep-Oct       Impact factor: 1.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.